Evidence map›Paper›PMID 32616746›Full record

ReviewNature reviews. Disease primers2020

Graves' disease.

Terry F Davies, Stig Andersen, Rauf Latif, Yuji Nagayama, Giuseppe Barbesino, Maria Brito, Anja K Eckstein, Alex Stagnaro-Green, George J Kahaly

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Disease primers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06068179 (The Efficacy and Safety of Combining Mycophenolate Mofetil With Methimazole on Remission of Newly Diagnosis Graves' Disease), which is not on this map. Cited by 225 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
225citing papers in PubMed, 10 pooled it
28.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06068179 phase2 / phase3recruitingnot on this mapstarted 2023, after this paper: background citation

The Efficacy and Safety of Combining Mycophenolate Mofetil With Methimazole on Remission of Newly Diagnosis Graves' Disease (3M-RGD Trial): an Open-label, Randomized Trial

TypeinterventionalSponsorThe First Affiliated Hospital of Xiamen UniversityRan2023 to 2026Enrolled205ConditionsGraves' DiseaseArmsMycophenolate Mofetil, Oral, 250 Mg, methimazole, oral, 10mg
3 · Its place in the literature

Who cites it

225 citing papers in PubMed, 10 syntheses or guidelines pooled it, 376 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Salivary Alterations in Autoimmune Thyroid Diseases: A Systematic Review.International journal of environmental research and public health · 2023
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

165 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 4 countries.

Terry F DaviesThyroid Research Laboratory, Icahn School of Medicine at Mount Sinai, New York, NY, USA. terry.davies@mssm.edu.
Stig AndersenDepartment of Geriatric and Internal Medicine and Arctic Health Research Center, Aalborg University Hospital, Aalborg, Denmark.
Rauf LatifThyroid Research Laboratory, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Yuji NagayamaDepartment of Molecular Medicine, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Giuseppe BarbesinoThyroid Unit, Division of Endocrinology, Massachusetts General Hospital, Boston, MA, USA.
Maria BritoMount Sinai Thyroid Center, Mount Sinai Downtown at Union Sq, New York, NY, USA.
Anja K EcksteinDepartment of Ophthalmology, University Duisburg Essen, Essen, Germany.
Alex Stagnaro-GreenDepartments of Medicine, Obstetrics and Gynecology and Medical Education, University of Illinois College of Medicine at Rockford, Rockford, IL, USA.
George J KahalyDepartment of Medicine I, Johannes Gutenberg University Medical Centre, Mainz, Germany.
Icahn School of Medicine at Mount Sinai · USAalborg University Hospital · DKMassachusetts General Hospital · USNagasaki University · JPUniversity Medical Center of the Johannes Gutenberg University Mainz · DEUniversity of Duisburg-Essen · DEUniversity of Illinois Chicago, Rockford campus · US

Funding

BLRD VA I01 BX000800
6 · The paper itself

Abstract

Graves' disease (GD) is an autoimmune disease that primarily affects the thyroid gland. It is the most common cause of hyperthyroidism and occurs at all ages but especially in women of reproductive age. Graves' hyperthyroidism is caused by autoantibodies to the thyroid-stimulating hormone receptor (TSHR) that act as agonists and induce excessive thyroid hormone secretion, releasing the thyroid gland from pituitary control. TSHR autoantibodies also underlie Graves' orbitopathy (GO) and pretibial myxoedema. Additionally, the pathophysiology of GO (and likely pretibial myxoedema) involves the synergism of insulin-like growth factor 1 receptor (IGF1R) with TSHR autoantibodies, causing retro-orbital tissue expansion and inflammation. Although the aetiology of GD remains unknown, evidence indicates a strong genetic component combined with random potential environmental insults in an immunologically susceptible individual. The treatment of GD has not changed substantially for many years and remains a choice between antithyroid drugs, radioiodine or surgery. However, antithyroid drug use can cause drug-induced embryopathy in pregnancy, radioiodine therapy can exacerbate GO and surgery can result in hypoparathyroidism or laryngeal nerve damage. Therefore, future studies should focus on improved drug management, and a number of important advances are on the horizon.

Indexed as

Anti-Retroviral AgentsDisease ManagementHIV InfectionsHumansnef Gene Products, Human Immunodeficiency VirusQuality of Lifetat Gene Products, Human Immunodeficiency Virusvpr Gene Products, Human Immunodeficiency VirusAnti-Retroviral Agentsnef Gene Products, Human Immunodeficiency Virustat Gene Products, Human Immunodeficiency Virusvpr Gene Products, Human Immunodeficiency Virus

Identifiers

PMID32616746
OpenAlexW4211209010

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.